DEF: CytoSorbents Sets Date for 2025 Annual Stockholders Meeting, Outlines Proposals

Sentiment:

Proxy Statement 23 April 2025 4:25 PM

CytoSorbents Corporation will hold its annual meeting of stockholders virtually on June 12, 2025, to vote on director elections, executive compensation, and auditor ratification.

Summary

CytoSorbents Corporation will hold its annual meeting of stockholders virtually on June 12, 2025, at 10:00 a.m. Eastern Time.
Stockholders of record as of April 17, 2025, are entitled to vote.
The meeting will address the election of five directors, an advisory vote on executive compensation, and the ratification of WithumSmith+Brown, PC as the independent auditor for the fiscal year ending December 31, 2025.
The Board recommends voting FOR the election of the director nominees, FOR the approval of executive compensation, and FOR the ratification of the auditor appointment.
Proxy materials are available online and were mailed to stockholders around April 23, 2025.
The board held fifteen meetings during the year ended December 31, 2024.
The company's insider trading policy prohibits transactions in puts, calls, or other derivative securities involving the company's equity securities, as well as hedging transactions involving the company's equity securities, such as collars and forward sale contracts.

Sentiment

Score: 7

Explanation: The document is primarily informational and procedural, with a neutral to slightly positive tone due to the Board's recommendations and focus on corporate governance best practices.

Positives

The virtual meeting format facilitates stockholder attendance and participation at no cost.
The company is providing access to proxy materials online to reduce paper and mailing costs.
The Board is recommending votes in favor of all proposals.
The company has a Code of Business Conduct and Ethics in place.
The company has policies prohibiting hedging and pledging of company stock by executive officers and board members.

Negatives

The vote on executive compensation is non-binding and advisory in nature.
The company voluntarily reduced salaries for certain named executive officers as part of cost-cutting measures.

Risks

Failure to ratify the appointment of the independent registered public accounting firm would require the Audit Committee to reconsider the appointment.
The company's success depends on attracting and retaining talented executives and business professionals in a competitive market.
The company faces risks related to the development and regulatory approval of its DrugSorb-ATR antithrombotic removal system.

Future Outlook

The company is focused on the development and regulatory approval of its DrugSorb-ATR antithrombotic removal system, with a De Novo medical device application submitted to the U.S. FDA in September 2024.

Management Comments

The Board believes that its current leadership structure with Dr. Chan serving as the Chief Executive Officer and Mr. Bator serving as our independent non-executive Chairman, is appropriate for the Company at this time as it promotes balance between the Boards independent authority to oversee our business and the Chief Executive Officer and his management team who manage the business on a day-to-day basis.
We believe this balance of shared leadership between the two positions is a strength for the Company.

Industry Context

The company competes for capital with other early-stage microcap and small-cap companies in the life sciences space and competes with pharmaceutical and medical device companies in attracting and retaining a skilled management team.

Comparison to Industry Standards

The Compensation Committee examines competitive compensation data for senior executives of other similar life science companies on the Nasdaq.
The company's compensation program is designed to offer market-competitive compensation and benefits to attract, retain, and motivate highly skilled individuals.
The company's compensation practices are compared with peer companies in the life sciences sector to ensure that compensation packages of key executives are tied to the long-term success of the company and therefore correlated to increases in stockholder value.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Chief Financial Officer	Kathleen P. Bloch	Peter J. Mariani	August 14, 2024	Retirement of Kathleen P. Bloch

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Director Independence	The Board has determined that Messrs. Bator, Sobel, Ms. Kim, and Dr. Jones are independent as defined under Nasdaq listing standards.	N/A	Ensures objective oversight of management.
Hedging and Pledging Policy	All executive officers and members of the Board are prohibited from entering into hedging or pledging transactions in respect of our Common Stock or other securities issued by us.	N/A	Aligns interests of executives and board members with those of shareholders.

Stakeholder Impact

Stockholders are provided with the opportunity to vote on key corporate matters.
Executive compensation is designed to align with the long-term interests of the company and its stockholders.
The company's governance practices aim to ensure transparency and accountability to stakeholders.

Next Steps

Stockholders are encouraged to vote their shares promptly.
The company will announce preliminary voting results at the Annual Meeting and publish finalized results in a Form 8-K.

Key Dates

Date	Description
March 5, 2025	Deadline for stockholder proposals to be included in proxy materials for the Annual Meeting.
April 17, 2025	Record date for determining stockholders eligible to vote at the Annual Meeting.
April 23, 2025	Approximate date of mailing the Notice of Internet Availability of Proxy Materials to stockholders.
May 29, 2025	Deadline to request a paper copy of the Proxy Materials.
June 11, 2025	Deadline for voting via the Internet or telephone.
June 12, 2025	Date of the Annual Meeting of Stockholders.
December 24, 2025	Deadline for stockholder proposals for inclusion in the 2026 proxy statement.
March 14, 2026	Latest date for stockholder proposals and director nominations for the 2026 annual meeting.
April 13, 2026	Deadline for stockholders to provide notice with information required by Exchange Act Rule 14a-19 for director nominations at the 2026 annual meeting.
June 12, 2026	Expected date of the next Say-on-Pay vote at the annual meeting of stockholders.

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Executive Compensation, Auditor, CytoSorbents, Voting, Governance

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.